Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis — Stella

Recruiting

Back to Amyloidosis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Oregon Health & Science University, Portland, Oregon

Key details

Phase

Safety & dosing

Sponsor

Oregon Health and Science University

Collaborators

Attralus, Inc., Bayer

Enrollment target

~150 participants

Started

January 2023

Primary completion

December 2027

Age range

40 Years – 90 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov